增强现实引导肝切除术的临床疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入5项研究共410例患者(AR组141例),评估增强现实引导肝切除术对比常规技术的疗效。结果显示AR引导可显著减少术中出血、降低输血率、减少切除相关并发症及肿瘤复发率,但在Clavien-Dindo分级、手术时间、肝衰竭、手术部位感染和住院时长方面无显著差异。
要点
- AR引导肝切除术可显著减少术中出血量(MD -75.9 mL)并降低输血率(RR 0.47)。
- AR引导可减少切除相关并发症(RR 0.64)及肝肿瘤患者复发率(RR 0.52)。
- Clavien-Dindo分级、手术时间、肝衰竭、SSI及住院时长未见显著差异。
核心结论
- AR引导肝切除术可显著减少术中出血、输血需求、切除相关并发症及肿瘤复发,支持其作为安全有效的工具。
研究设计与样本
- 遵循PRISMA 2020指南的系统综述与荟萃分析,检索Embase、PubMed和Cochrane Library,最终纳入5项比较研究,共410例患者(AR组141例),男性占56%,平均年龄57岁。
主要发现
- AR组术中出血量显著减少(MD -75.9 mL;95%CI -103.4至-48.3;p<0.001)。
- AR组输血率显著降低(RR 0.47;95%CI 0.26至0.85;p=0.01)。
- AR组切除相关并发症显著减少(RR 0.64;95%CI 0.46至0.90;p=0.009)。
- 肝肿瘤患者亚组分析显示AR组复发率显著降低(RR 0.52;95%CI 0.34至0.79;p=0.002)。
- Clavien-Dindo分级、手术时间、肝衰竭、SSI及住院时长在两组间无显著差异。
临床怎么用
- 对于肝切除术,可考虑采用AR(尤其联合ICG荧光)引导以提升切除精度、减少出血和并发症。
- 肝肿瘤患者应用AR引导可能有助于降低术后复发风险。
局限性
- 纳入研究数量少(仅5项),方法学存在变异性,结论需谨慎解读并需进一步研究标准化应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Liver resection is technically challenging due to the liver's anatomical complexity. Augmented reality (AR), especially when combined with indocyanine green (ICG) fluorescence, has been adopted to enhance resection precision, reduce intraoperative complications, and improve outcomes. This systematic review and meta-analysis aimed to evaluate whether AR-guided liver surgery is associated with reduced intraoperative bleeding and improved clinical outcomes compared to conventional techniques. METHODS: A comprehensive search was conducted in Embase, PubMed, and the Cochrane Library, following PRISMA 2020 guidelines. Studies comparing AR-guided liver resections were included. Outcomes analyzed included blood loss, transfusion rates, Clavien-Dindo classification, operative time, liver failure, surgical site infection (SSI), resection-related complications, hospital stay length, and tumor recurrence. Statistical analysis was performed using Review Manager 5.4 and R Studio 4.5, applying a random-effects model when heterogeneity was high. RESULTS: Of 284 identified studies, 5 met inclusion criteria, totaling 410 patients (AR group n = 141), with 56% male and a mean age of 57 years. AR use was significantly associated with reduced blood loss (MD: -75.9 mL; 95% CI -103.4 to -48.3; p < 0.001), lower transfusion rates (RR: 0.47; 95% CI 0.26 to 0.85; p = 0.01), and fewer resection-related complications (RR: 0.64; 95% CI 0.46 to 0.90; p = 0.009). Subgroup analysis in patients with liver tumors confirmed these benefits, including a lower recurrence rate (RR: 0.52; 95% CI 0.34 to 0.79; p = 0.002). No significant differences were found for Clavien-Dindo classification, operative time, liver failure, SSI, or hospital stay duration. CONCLUSION: AR-guided liver surgery demonstrated significant clinical benefits, notably reducing intraoperative bleeding, transfusion needs, resection-related complications, and tumor recurrence. Despite limitations in study number and methodological variability, this meta-analysis supports AR as a safe and effective tool in liver surgery, warranting further research to standardize its application.
引用
- Cesconetto RM, Graziani E Sousa A, Santos Saraiva V, et al. Clinical efficacy and safety of augmented reality-guided hepatic resection: a systematic review and meta-analysis. Surg Endosc. 2025. PMID: 41430466. doi:10.1007/s00464-025-12496-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。